These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 37526266)
1. Modular Titratable Polypills for Personalized Medicine and Simplification of Complex Medication Regimens. Karavasili C; Babaee S; Kutty S; Chu JN; Min S; Fitzgerald N; Morimoto J; Inverardi N; Traverso G Adv Healthc Mater; 2023 Oct; 12(27):e2301101. PubMed ID: 37526266 [TBL] [Abstract][Full Text] [Related]
2. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk. Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A; Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727 [TBL] [Abstract][Full Text] [Related]
3. The Effect of a Cardiovascular Polypill Strategy on Pill Burden. Truelove M; Patel A; Bompoint S; Brown A; Cass A; Hillis GS; Peiris D; Rafter N; Reid CM; Rodgers A; Tonkin A; Usherwood T; Webster R; Cardiovasc Ther; 2015 Dec; 33(6):347-52. PubMed ID: 26280247 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial. Singh K; Crossan C; Laba TL; Roy A; Hayes A; Salam A; Jan S; Lord J; Tandon N; Rodgers A; Patel A; Thom S; Prabhakaran D Int J Cardiol; 2018 Jul; 262():71-78. PubMed ID: 29622506 [TBL] [Abstract][Full Text] [Related]
5. A polypill strategy to improve adherence: results from the FOCUS project. Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393 [TBL] [Abstract][Full Text] [Related]
6. [The polypill for cardiovascular disease: why is it used so infrequently?]. Bots ML; Lafeber M Ned Tijdschr Geneeskd; 2018 Dec; 162():. PubMed ID: 30570925 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK. Becerra V; Gracia A; Desai K; Abogunrin S; Brand S; Chapman R; García Alonso F; Fuster V; Sanz G BMJ Open; 2015 May; 5(5):e007111. PubMed ID: 25991449 [TBL] [Abstract][Full Text] [Related]
8. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy? Franczyk B; Gluba-Brzózka A; Jurkiewicz Ł; Penson P; Banach M; Rysz J Expert Opin Pharmacother; 2018 Dec; 19(17):1857-1865. PubMed ID: 30295098 [TBL] [Abstract][Full Text] [Related]
9. Barriers and Facilitators to the Use of Cardiovascular Fixed-Dose Combination Medication (Polypills) in Andhra Pradesh, India: A Mixed-Methods Study. Salam A; Praveen D; Patel A; Tewari A; Webster R Glob Heart; 2019 Sep; 14(3):303-310. PubMed ID: 31451238 [TBL] [Abstract][Full Text] [Related]
10. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease. Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A; Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587 [TBL] [Abstract][Full Text] [Related]
11. Polypill Variants (Quarter Pill Trials). Teo K; Yusuf S Am J Hypertens; 2018 Jun; 31(7):758-761. PubMed ID: 29554202 [TBL] [Abstract][Full Text] [Related]
12. Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease. Wood F; Salam A; Singh K; Day S; Jan S; Prabhakaran D; Rodgers A; Patel A; Thom S; Ward H BMJ Open; 2015 Sep; 5(9):e008018. PubMed ID: 26423850 [TBL] [Abstract][Full Text] [Related]
13. Redefining the polypill: pros and cons in cardiovascular precision medicine. Birla S; Angural A; Madathumchalil A; Shende RV; Shastry SV; Mahadevappa M; Shambhu SK; Vishwanath P; Prashant A Front Pharmacol; 2023; 14():1268119. PubMed ID: 37799963 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study. Lin JK; Moran AE; Bibbins-Domingo K; Falase B; Pedroza Tobias A; Mandke CN; Kazi DS Lancet Glob Health; 2019 Oct; 7(10):e1346-e1358. PubMed ID: 31477544 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review. Jahangiri R; Rezapour A; Malekzadeh R; Olyaeemanesh A; Roshandel G; Motevalian SA PLoS One; 2022; 17(7):e0271908. PubMed ID: 35901100 [TBL] [Abstract][Full Text] [Related]
16. Patients' and providers' perspectives of a polypill strategy to improve cardiovascular prevention in Australian primary health care: a qualitative study set within a pragmatic randomized, controlled trial. Liu H; Massi L; Laba TL; Peiris D; Usherwood T; Patel A; Cass A; Eades AM; Redfern J; Hayman N; Howard K; Brien JA; Jan S Circ Cardiovasc Qual Outcomes; 2015 May; 8(3):301-8. PubMed ID: 25944629 [TBL] [Abstract][Full Text] [Related]
17. Impact of switching to polypill based therapy by baseline potency of medication: Post-hoc analysis of the SPACE Collaboration dataset. Webster R; Bullen C; Patel A; Selak V; Stepien S; Thom S; Rodgers A Int J Cardiol; 2017 Dec; 249():443-447. PubMed ID: 28986058 [TBL] [Abstract][Full Text] [Related]
18. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A; Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715 [TBL] [Abstract][Full Text] [Related]
19. 'Temporary Plasticiser': A novel solution to fabricate 3D printed patient-centred cardiovascular 'Polypill' architectures. Pereira BC; Isreb A; Forbes RT; Dores F; Habashy R; Petit JB; Alhnan MA; Oga EF Eur J Pharm Biopharm; 2019 Feb; 135():94-103. PubMed ID: 30579852 [TBL] [Abstract][Full Text] [Related]
20. Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial. Ostovaneh MR; Poustchi H; Hemming K; Marjani H; Pourshams A; Nateghi A; Majed M; Navabakhsh B; Khoshnia M; Jaafari E; Mohammadifard N; Malekzadeh F; Merat S; Sadeghi M; Naemi M; Etemadi A; Thomas GN; Sarrafzadegan N; Cheng KK; Marshall T; Malekzadeh R Eur J Prev Cardiol; 2015 Dec; 22(12):1609-17. PubMed ID: 25230980 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]